Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336201 · ClinicalTrials.gov registry record · Phase 2
Cognitive Remediation Intervention to Prepare for Transition of Care
A Phase 2 study of Sickle Cell Disease and Cognitive Impairment, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05336201: Recruiting Phase 2 study of Sickle Cell Disease and Cognitive Impairment, sponsored by University of Alabama at Birmingham.
NCT05336201 is a Phase 2 study of Sickle Cell Disease and Cognitive Impairment that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05336201, a Phase 2 study of Sickle Cell Disease and Cognitive Impairment, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Primary Outcome
Questionnaire assessing how knowledgeable the youth is about their health condition and the skills necessary for self-management and self-advocacy
Conditions Studied
Interventions
- BEHAVIORAL CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT05336201 shows while recruiting
NCT05336201 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower).
The record links to 6 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) is the first listed.
NCT05336201 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05336201 about?
NCT05336201 is a clinical study titled "Cognitive Remediation Intervention to Prepare for Transition of Care". Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
What is the current status of trial NCT05336201?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT05336201 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Coping Skills.
What interventions are being tested in trial NCT05336201?
The interventions under investigation include: CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05336201?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336201 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05336201's enrollment target sits among peer trials
120 51st of 213 higher than 159 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI